Search Results - "Conroy, T"

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Ducreux, M., Cuhna, A. Sa, Caramella, C., Hollebecque, A., Burtin, P., Goéré, D., Seufferlein, T., Haustermans, K., Van Laethem, J.L., Conroy, T., Arnold, D.

Get full text

Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Conroy, T., Pfeiffer, P., Vilgrain, V., Lamarca, A., Seufferlein, T., O’Reilly, E.M., Hackert, T., Golan, T., Prager, G., Haustermans, K., Vogel, A., Ducreux, M.

“…•The guideline covers diagnosis, staging, risk assessment, treatment, disease monitoring and follow-up.•The multidisciplinary expert author group is from…”
Get full text

Reply to the Letter to the Editor 'Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten' (in regard to "Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up") by Huguet et al by Conroy, T, Haustermans, K, Ducreux, M

Get more information

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer by Azria, D., Doyen, J., Jarlier, M., Martel-Lafay, I., Hennequin, C., Etienne, P., Vendrely, V., François, E., de La Roche, G., Bouché, O., Mirabel, X., Denis, B., Mineur, L., Berdah, J., Mahé, M., Bécouarn, Y., Dupuis, O., Lledo, G., Seitz, J., Bedenne, L., Gourgou-Bourgade, S., Juzyna, B., Conroy, T., Gérard, J.

“…Outcome of intermediate risk rectal cancer may be improved by the addition of oxaliplatin during 5-fluoruracil concomitant neoadjuvant chemoradiotherapy. The…”
Get full text

Is neoadjuvant folfox an effective treatment only in a very selected favorable subgroup of locally advanced rectal cancer? by Riou, O., Castan, F., Conroy, T.

Get full text

Validation and optimization of the French Generic Adherence for Chronic Diseases Profile (GACID-P) using classical test and item response theory by Rotonda, Christine, Guillemin, F, Conroy, T, Alleyrat, C, Lefevre, B, Soudant, M, Tarquinio, C

“…The Generic Adherence for Chronic Diseases Profile is a French generic scale (GACID-P) developed to measure adherence in several disease areas such as…”
Get full text

Impacts of 150 Years of Shoreline and Bathymetric Change in the Coos Estuary, Oregon, USA by Eidam, E.F., Sutherland, D.A., Ralston, D.K., Dye, B., Conroy, T., Schmitt, J., Ruggiero, P., Wood, J.

“…Estuaries worldwide have evolved over the past few centuries under development activities like dredging and shoreline reclamation, which commonly lead to…”
Get full text

An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45 by Bjelic-Radisic, V., Cardoso, F., Cameron, D., Brain, E., Kuljanic, K., da Costa, R.A., Conroy, T., Inwald, E.C., Serpentini, S., Pinto, M., Weis, J., Morag, O., Lindviksmoen Astrup, G., Tomaszweksi, K.A., Pogoda, K., Sinai, P., Sprangers, M., Aaronson, N., Velikova, G., Greimel, E., Arraras, J., Bottomley, A., Bleiker, Eveline, Bliem, Brigitte, Chie, Weichu, Creutzberg, Carien, Deville, Valerie, Duhoux, Francois, Eilf, Kirsten, Hartup, Sue, Koller, Michael, Nagele, Eva, Nicolatou-Galitis, Ourania, Oberguggenberger, Anne, Schmalz, Claudia, Winters, Zoe

“…The European Organization for Research and Treatment of Cancer (EORTC) QLQ-BR23 was one of the first disease-specific questionnaires developed in 1996 to…”
Get full text

Development and psychometric evaluation of item banks for memory and attention – supplements to the EORTC CAT Core instrument by Rogge, AA, Petersen, MA, Aaronson, NK, Conroy, T, Dirven, L, Fischer, F, Habets, EJJ, Reijneveld, JC, Rose, M, Sleurs, C, Taphoorn, M, Tomaszewski, KA, Vachon, H, Young, T, Groenvold, M

“…Abstract Background Cancer patients may experience a decrease in cognitive functioning before, during and after cancer treatment. So far, the Quality of Life…”
Get full text

Handling informative dropout in longitudinal analysis of health-related quality of life: application of three approaches to data from the esophageal cancer clinical trial PRODIGE 5/ACCORD 17 by Cuer, B, Mollevi, C, Anota, A, Charton, E, Juzyna, B, Conroy, T, Touraine, C

“…Health-related quality of life (HRQoL) has become a major endpoint to assess the clinical benefit of new therapeutic strategies in oncology clinical trials…”
Get full text

Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer by Whistance, R.N, Conroy, T, Chie, W, Costantini, A, Sezer, O, Koller, M, Johnson, C.D, Pilkington, S.A, Arraras, J, Ben-Josef, E, Pullyblank, A.M, Fayers, P, Blazeby, J.M

“…Abstract This international study aimed to test the measurement properties of the updated European Organisation for Research and Treatment of Cancer (EORTC)…”
Get full text

Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma by Fraunhoffer, N, Hammel, P, Conroy, T, Nicolle, R, Bachet, J-B, Harlé, A, Rebours, V, Turpin, A, Ben Abdelghani, M, Mitry, E, Biagi, J, Chanez, B, Bigonnet, M, Lopez, A, Evesque, L, Lecomte, T, Assenat, E, Bouché, O, Renouf, D J, Lambert, A, Monard, L, Mauduit, M, Cros, J, Iovanna, J, Dusetti, N

“…After surgical resection of pancreatic ductal adenocarcinoma (PDAC), patients are predominantly treated with adjuvant chemotherapy, commonly consisting of…”
Get more information

Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS) by Adenis, A., Bennouna, J., Etienne, P.L., Bogart, E., Francois, E., Galais, M.P., Ben Abdelghani, M., Michel, P., Metges, J.P., Dahan, L., Conroy, T., Ghiringhelli, F., Drouillard, A., El Hajbi, F., Samalin, E., Hiret, S., Delaine-Clisant, S., Mariette, C., Penel, N., Piessen, G., Le Deley, M.C.

“…The role of chemotherapy has not been established in the treatment of metastatic squamous cell oesophageal cancer (mESCC). E-DIS is a discontinuation trial,…”
Get full text

Lessons Learned from the Preimplementation Phase of an Oral Health Care Project by Murray, J., Hunter, S.C., Splawinski, Z., Conroy, T.

“…Implementation research aims to improve uptake of evidence-based interventions into health care practice and policy, but conducting such research can be…”
Get full text

Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial by Deutsch, E., Lemanski, C., Pignon, J.P., Levy, A., Delarochefordiere, A., Martel-Lafay, I., Rio, E., Malka, D., Conroy, T., Miglianico, L., Becouarn, Y., Malekzadeh, K., Paris, E., Juzyna, B., Ezra, P., Azria, D.

“…The ACCORD 16 phase II trial aimed to evaluate the objective response rate after combination of conventional chemoradiotherapy (CRT) and cetuximab in locally…”
Get full text

What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question? by Bonnetain, F, Bosset, J.F, Gerard, J.P, Calais, G, Conroy, T, Mineur, L, Bouché, O, Maingon, P, Chapet, O, Radosevic-Jelic, L, Methy, N, Collette, L

“…Abstract Background Two phase III trials of neoadjuvant treatment in T3-4 rectal cancer established that adding chemotherapy (CRT) to radiotherapy (RT)…”
Get full text

New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel by Van Laethem, J.-L., Verslype, C., Iovanna, J.L., Michl, P., Conroy, T., Louvet, C., Hammel, P., Mitry, E., Ducreux, M., Maraculla, T., Uhl, W., Van Tienhoven, G., Bachet, J.B., Maréchal, R., Hendlisz, A., Bali, M., Demetter, P., Ulrich, F., Aust, D., Luttges, J., Peeters, M., Mauer, M., Roth, A., Neoptolemos, J.P., Lutz, M.

“…Although the treatment of pancreatic ductal adenocarcinoma (PDAC) remains a huge challenge, it is entering a new era with the development of new strategies and…”
Get full text

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802) by Ychou, M., Raoul, J.-L., Douillard, J.-Y., Gourgou-Bourgade, S., Bugat, R., Mineur, L., Viret, F., Becouarn, Y., Bouché, O., Gamelin, E., Ducreux, M., Conroy, T., Seitz, J.-F., Bedenne, L., Kramar, A.

“…Background: This multicenter adjuvant phase III trial evaluated the addition of irinotecan to LV5FU2 in colon cancer patients at high risk of relapse. Patients…”
Get full text

Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancer by Bascoul-Mollevi, C., Gourgou, S., Galais, M.-P., Raoul, J.-L., Bouché, O., Douillard, J.-Y., Adenis, A., Etienne, P.-L., Juzyna, B., Bedenne, L., Conroy, T.

“…A recent prospective randomised trial did not reveal significant differences in median progression-free survival between two chemoradiotherapy (CRT) regimens…”
Get full text

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France by Blay, J.Y., Boucher, S., Le Vu, B., Cropet, C., Chabaud, S., Perol, D., Barranger, E., Campone, M., Conroy, T., Coutant, C., De Crevoisier, R., Debreuve-Theresette, A., Delord, J.P., Fumoleau, P., Gentil, J., Gomez, F., Guerin, O., Jaffré, A., Lartigau, E., Lemoine, C., Mahe, M.A., Mahon, F.X., Mathieu-Daude, H., Merrouche, Y., Penault-Llorca, F., Pivot, X., Soria, J.C., Thomas, G., Vera, P., Vermeulin, T., Viens, P., Ychou, M., Beaupere, S.

“…The impact of the first coronavirus disease 2019 (COVID-19) wave on cancer patient management was measured within the nationwide network of the Unicancer…”
Get full text